;PMID: 9797363
;source_file_1391.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:45..129] = [t:45..129]
;2)section:[e:133..267] = [t:133..267]
;3)section:[e:271..358] = [t:271..358]
;4)sentence:[e:362..380] = [t:362..380]
;5)sentence:[e:381..437] = [t:381..437]
;6)sentence:[e:439..547] = [t:439..547]
;7)sentence:[e:548..753] = [t:548..753]
;8)sentence:[e:754..826] = [t:754..826]
;9)sentence:[e:828..836] = [t:828..836]
;10)sentence:[e:837..1074] = [t:837..1074]
;11)sentence:[e:1075..1119] = [t:1075..1119]
;12)sentence:[e:1120..1261] = [t:1120..1261]
;13)sentence:[e:1262..1270] = [t:1262..1270]
;14)sentence:[e:1271..1366] = [t:1271..1366]
;15)sentence:[e:1367..1459] = [t:1367..1459]
;16)sentence:[e:1460..1472] = [t:1460..1472]
;17)sentence:[e:1473..1636] = [t:1473..1636]
;18)section:[e:1640..1684] = [t:1640..1684]

;section 0 Span:0..40
;Gastroenterology  1998 Nov;115(5):1090-5
(SEC
  (FRAG (IN:[0..16] Gastroenterology) (CD:[18..22] 1998)
        (CD:[23..31] Nov;115-LRB-) (CD:[31..32] 5) (-RRB-:[32..33] -RRB-)
        (CD:[33..38] :1090) (HYPH:[38..39] -) (CD:[39..40] 5)))

;sentence 1 Span:45..129
;A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal 
;tumors.
;[82..87]:gene-rna:"c-kit"
;[96..128]:malignancy:"gastrointestinal stromal  tumors"
(SENT
  (NP-HLN
    (NP (DT:[45..46] A) (JJ:[47..52] novel)
      (NML
        (NML (NN:[53..57] gain))
        (HYPH:[57..58] -)
        (PP (IN:[58..60] of) (HYPH:[60..61] -)
          (NP (NN:[61..69] function))))
      (NN:[70..78] mutation))
    (PP (IN:[79..81] of)
      (NP (NN:[82..87] c-kit) (NN:[88..92] gene)))
    (PP (IN:[93..95] in)
      (NP (JJ:[96..112] gastrointestinal) (JJ:[113..120] stromal)
          (NNS:[122..128] tumors)))
    (.:[128..129] .)))

;section 2 Span:133..267
;Nakahara M, Isozaki K, Hirota S, Miyagawa J, Hase-Sawada N, Taniguchi M,
;Nishida  T, Kanayama S, Kitamura Y, Shinomura Y, Matsuzawa Y.
(SEC
  (FRAG (NNP:[133..141] Nakahara) (NNP:[142..144] M,) (NNP:[145..152] Isozaki)
        (NNP:[153..154] K) (,:[154..155] ,) (NNP:[156..162] Hirota)
        (NNP:[163..165] S,) (NNP:[166..174] Miyagawa) (NNP:[175..177] J,)
        (NNP:[178..182] Hase) (HYPH:[182..183] -) (NNP:[183..189] Sawada)
        (NNP:[190..191] N) (,:[191..192] ,) (NNP:[193..202] Taniguchi)
        (VBD:[203..205] M,) (NNP:[206..213] Nishida) (NNP:[215..216] T)
        (,:[216..217] ,) (NNP:[218..226] Kanayama) (NNP:[227..229] S,)
        (NNP:[230..238] Kitamura) (NNP:[239..240] Y) (,:[240..241] ,)
        (NNP:[242..251] Shinomura) (NNP:[252..253] Y) (,:[253..254] ,)
        (NNP:[255..264] Matsuzawa) (NNP:[265..267] Y.)))

;section 3 Span:271..358
;Second Department of Internal Medicine, Osaka University Medical School,
;Osaka,  Japan.
(SEC
  (FRAG (NNP:[271..277] Second) (NNP:[278..288] Department) (DT:[289..291] of)
        (NNP:[292..300] Internal) (NNP:[301..309] Medicine) (,:[309..310] ,)
        (NNP:[311..316] Osaka) (NNP:[317..327] University)
        (NNP:[328..335] Medical) (NNP:[336..342] School) (,:[342..343] ,)
        (NNP:[344..349] Osaka) (IN:[349..350] ,) (NNP:[352..357] Japan)
        (.:[357..358] .)))

;sentence 4 Span:362..380
;BACKGROUND & AIMS:
(SENT
  (NP (NN:[362..372] BACKGROUND) (CC:[373..374] &) (NNS:[375..379] AIMS)
      (::[379..380] :)))

;sentence 5 Span:381..437
;The c-kit gene encodes a receptor tyrosine kinase (KIT).
;[385..390]:gene-rna:"c-kit"
;[406..430]:gene-protein:"receptor tyrosine kinase"
;[432..435]:gene-protein:"KIT"
(SENT
  (S
    (NP-SBJ (DT:[381..384] The) (NN:[385..390] c-kit) (NN:[391..395] gene))
    (VP (VBZ:[396..403] encodes)
      (NP (DT:[404..405] a) (NN:[406..414] receptor)
        (NML
          (NML (NN:[415..423] tyrosine) (NN:[424..430] kinase))
          (NML (-LRB-:[431..432] -LRB-) (NN:[432..435] KIT)
               (-RRB-:[435..436] -RRB-)))))
    (.:[436..437] .)))

;sentence 6 Span:439..547
;Recently, we found gain-of-function mutations of the c-kit gene in 
;gastrointestinal stromal tumors (GISTs).
;[492..497]:gene-rna:"c-kit"
;[507..538]:malignancy:"gastrointestinal stromal tumors"
;[540..545]:malignancy:"GISTs"
(SENT
  (S
    (ADVP-TMP (RB:[439..447] Recently))
    (,:[447..448] ,)
    (NP-SBJ (PRP:[449..451] we))
    (VP (VBD:[452..457] found)
      (NP
        (NP
          (NML
            (NML (NN:[458..462] gain))
            (HYPH:[462..463] -)
            (PP (IN:[463..465] of) (HYPH:[465..466] -)
              (NP (NN:[466..474] function))))
          (NNS:[475..484] mutations))
        (PP (IN:[485..487] of)
          (NP
            (NP (DT:[488..491] the) (NN:[492..497] c-kit) (NN:[498..502] gene))
            (PP-LOC (IN:[503..505] in)
              (NP
                (NP (JJ:[507..523] gastrointestinal) (JJ:[524..531] stromal)
                    (NNS:[532..538] tumors))
                (NP (-LRB-:[539..540] -LRB-) (NNS:[540..545] GISTs)
                    (-RRB-:[545..546] -RRB-))))))))
    (.:[546..547] .)))

;sentence 7 Span:548..753
;All mutations were confined within the  11 amino acids (Lys-550 to Val-560)
;in the juxtamembrane domain, but one GIST  showed a novel deletion-type
;mutation at codon 579 (Asp) in the juxtamembrane  domain.
;[552..561]:variation-event:"mutations"
;[604..622]:variation-location:"Lys-550 to Val-560"
;[661..665]:malignancy:"GIST"
;[682..690]:variation-type:"deletion"
;[696..704]:variation-event:"mutation"
;[708..717]:variation-location:"codon 579"
;[719..722]:variation-state-original:"Asp"
(SENT
  (S
    (S
      (NP-SBJ-1 (DT:[548..551] All) (NNS:[552..561] mutations))
      (VP (VBD:[562..566] were)
        (VP (VBN:[567..575] confined)
          (NP-1 (-NONE-:[575..575] *))
          (PP (IN:[576..582] within)
            (NP
              (NP (DT:[583..586] the) (CD:[588..590] 11) (JJ:[591..596] amino)
                  (NNS:[597..602] acids)
                (PRN (-LRB-:[603..604] -LRB-)
                  (NP
                    (NP (NN:[604..611] Lys-550))
                    (PP (TO:[612..614] to)
                      (NP (NN:[615..622] Val-560))))
                  (-RRB-:[622..623] -RRB-)))
              (PP-LOC (IN:[624..626] in)
                (NP (DT:[627..630] the) (NN:[631..644] juxtamembrane)
                    (NN:[645..651] domain))))))))
    (,:[651..652] ,) (CC:[653..656] but)
    (S
      (NP-SBJ (CD:[657..660] one) (NN:[661..665] GIST))
      (VP (VBD:[667..673] showed)
        (NP (DT:[674..675] a) (JJ:[676..681] novel)
          (NML (NN:[682..690] deletion) (HYPH:[690..691] -) (NN:[691..695] type))
          (NN:[696..704] mutation))
        (PP-LOC (IN:[705..707] at)
          (NP
            (NP
               (NN:[708..713] codon) (CD:[714..717] 579)
              (PRN (-LRB-:[718..719] -LRB-)
                (NP (NN:[719..722] Asp))
                (-RRB-:[722..723] -RRB-)))
            (PP-LOC (IN:[724..726] in)
              (NP (DT:[727..730] the) (NN:[731..744] juxtamembrane)
                  (NN:[746..752] domain)))))))
    (.:[752..753] .)))

;sentence 8 Span:754..826
;The aim of this study was to clarify whether the mutation is activating.
;[803..811]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[754..757] The) (NN:[758..761] aim))
      (PP (IN:[762..764] of)
        (NP (DT:[765..769] this) (NN:[770..775] study))))
    (VP (VBD:[776..779] was)
      (S-NOM-PRD
        (NP-SBJ (-NONE-:[779..779] *))
        (VP (TO:[780..782] to)
          (VP (VB:[783..790] clarify)
            (SBAR (IN:[791..798] whether)
              (S
                (NP-SBJ (DT:[799..802] the) (NN:[803..811] mutation))
                (VP (VBZ:[812..814] is)
                  (ADJP-PRD (VBG:[815..825] activating)))))))))
    (.:[825..826] .)))

;sentence 9 Span:828..836
;METHODS:
(SENT
  (NP (NNS:[828..835] METHODS) (::[835..836] :)))

;sentence 10 Span:837..1074
;Mutant c-kit cDNA was transfected into an interleukin 3  (IL-3)-dependent
;Ba/F3 murine lymphoid cell line, and the magnitude of  autophosphorylation of
;the mutant KIT was examined with or without stem cell  factor (SCF), a ligand
;of KIT.
;[844..849]:gene-rna:"c-kit"
;[879..892]:gene-protein:"interleukin 3"
;[895..899]:gene-protein:"IL-3"
;[1000..1003]:gene-protein:"KIT"
;[1033..1050]:gene-protein:"stem cell  factor"
;[1052..1055]:gene-protein:"SCF"
;[1070..1073]:gene-protein:"KIT"
(SENT
  (S
    (S
      (NP-SBJ-2 (JJ:[837..843] Mutant) (NN:[844..849] c-kit)
                (NN:[850..854] cDNA))
      (VP (VBD:[855..858] was)
        (VP (VBN:[859..870] transfected)
          (NP-2 (-NONE-:[870..870] *))
          (PP (IN:[871..875] into)
            (NP (DT:[876..878] an)
              (ADJP
                (NML
                  (NML (NN:[879..890] interleukin) (CD:[891..892] 3))
                  (NML (-LRB-:[894..895] -LRB-) (NN:[895..899] IL-3)
                       (-RRB-:[899..900] -RRB-)))
                (HYPH:[900..901] -) (JJ:[901..910] dependent))
              (NML (NN:[911..913] Ba) (SYM:[913..914] /) (NN:[914..916] F3))
              (JJ:[917..923] murine) (JJ:[924..932] lymphoid)
               (NN:[933..937] cell) (NN:[938..942] line))))))
    (,:[942..943] ,) (CC:[944..947] and)
    (S
      (NP-SBJ-1
        (NP (DT:[948..951] the) (NN:[952..961] magnitude))
        (PP (IN:[962..964] of)
          (NP
            (NP (NN:[966..985] autophosphorylation))
            (PP (IN:[986..988] of)
              (NP (DT:[989..992] the) (JJ:[993..999] mutant)
                  (NN:[1000..1003] KIT))))))
      (VP (VBD:[1004..1007] was)
        (VP (VBN:[1008..1016] examined)
          (NP-1 (-NONE-:[1016..1016] *))
          (PP (IN:[1017..1021] with) (CC:[1022..1024] or)
              (IN:[1025..1032] without)
            (NP
              (NP
                (NP (NN:[1033..1037] stem) (NN:[1038..1042] cell)
                    (NN:[1044..1050] factor))
                (NP (-LRB-:[1051..1052] -LRB-) (NN:[1052..1055] SCF)
                    (-RRB-:[1055..1056] -RRB-)))
              (,:[1056..1057] ,)
              (NP
                (NP (DT:[1058..1059] a) (NN:[1060..1066] ligand))
                (PP (IN:[1067..1069] of)
                  (NP (NN:[1070..1073] KIT)))))))))
    (.:[1073..1074] .)))

;sentence 11 Span:1075..1119
;An in vitro kinase assay was also performed.
;[1087..1093]:gene-protein:"kinase"
(SENT
  (S
    (NP-SBJ-1 (DT:[1075..1077] An)
      (ADJP (FW:[1078..1080] in) (FW:[1081..1086] vitro))
      (NN:[1087..1093] kinase) (NN:[1094..1099] assay))
    (VP (VBD:[1100..1103] was)
      (ADVP (RB:[1104..1108] also))
      (VP (VBN:[1109..1118] performed)
        (NP-1 (-NONE-:[1118..1118] *))))
    (.:[1118..1119] .)))

;sentence 12 Span:1120..1261
;The  biological behavior of the transfectant was estimated by both an in
;vitro  proliferation assay and in vivo transplantation to nude mice.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1120..1123] The) (JJ:[1125..1135] biological)
          (NN:[1136..1144] behavior))
      (PP (IN:[1145..1147] of)
        (NP (DT:[1148..1151] the) (NN:[1152..1164] transfectant))))
    (VP (VBD:[1165..1168] was)
      (VP (VBN:[1169..1178] estimated)
        (NP-1 (-NONE-:[1178..1178] *))
        (PP (IN:[1179..1181] by)
          (NP (CC:[1182..1186] both)
            (NP (DT:[1187..1189] an)
              (ADJP (FW:[1190..1192] in) (FW:[1193..1198] vitro))
              (NN:[1200..1213] proliferation) (NN:[1214..1219] assay))
            (CC:[1220..1223] and)
            (NP
              (NP
                (ADJP (FW:[1224..1226] in) (FW:[1227..1231] vivo))
                (NN:[1232..1247] transplantation))
              (PP (TO:[1248..1250] to)
                (NP (JJ:[1251..1255] nude) (NNS:[1256..1260] mice))))))))
    (.:[1260..1261] .)))

;sentence 13 Span:1262..1270
;RESULTS:
(SENT
  (NP (NNS:[1262..1269] RESULTS) (::[1269..1270] :)))

;sentence 14 Span:1271..1366
;The  mutant KIT exhibited constitutive phosphorylation and strong kinase
;activity  without SCF.
;[1283..1286]:gene-protein:"KIT"
;[1337..1343]:gene-protein:"kinase"
;[1362..1365]:gene-protein:"SCF"
(SENT
  (S
    (NP-SBJ (DT:[1271..1274] The) (JJ:[1276..1282] mutant) (NN:[1283..1286] KIT))
    (VP (VBD:[1287..1296] exhibited)
      (NP
        (NP (JJ:[1297..1309] constitutive) (NN:[1310..1325] phosphorylation))
        (CC:[1326..1329] and)
        (NP (JJ:[1330..1336] strong) (NN:[1337..1343] kinase)
            (NN:[1344..1352] activity)))
      (PP (IN:[1354..1361] without)
        (NP (NN:[1362..1365] SCF))))
    (.:[1365..1366] .)))

;sentence 15 Span:1367..1459
;The transfectant grew autonomously without IL-3 and SCF, and it  formed
;tumors in nude mice.
;[1410..1414]:gene-protein:"IL-3"
;[1419..1422]:gene-protein:"SCF"
;[1439..1445]:malignancy:"tumors"
(SENT
  (S
    (S
      (NP-SBJ (DT:[1367..1370] The) (NN:[1371..1383] transfectant))
      (VP (VBD:[1384..1388] grew)
        (ADVP (RB:[1389..1401] autonomously))
        (PP (IN:[1402..1409] without)
          (NP (NN:[1410..1414] IL-3) (CC:[1415..1418] and) (NN:[1419..1422] SCF)))))
    (,:[1422..1423] ,) (CC:[1424..1427] and)
    (S
      (NP-SBJ (PRP:[1428..1430] it))
      (VP (VBD:[1432..1438] formed)
        (NP (NNS:[1439..1445] tumors))
        (PP-LOC (IN:[1446..1448] in)
          (NP (JJ:[1449..1453] nude) (NNS:[1454..1458] mice)))))
    (.:[1458..1459] .)))

;sentence 16 Span:1460..1472
;CONCLUSIONS:
(SENT
  (NP (NNS:[1460..1471] CONCLUSIONS) (::[1471..1472] :)))

;sentence 17 Span:1473..1636
;Deletion at codon 579 (Asp) in the  juxtamembrane domain of the c-kit gene is
;a novel gain-of-function mutation  other than the region between Lys-550 and
;Val-560.
;[1473..1481]:variation-type:"Deletion"
;[1485..1494]:variation-location:"codon 579"
;[1496..1499]:variation-state-original:"Asp"
;[1537..1542]:gene-rna:"c-kit"
;[1576..1584]:variation-event:"mutation"
;[1601..1635]:variation-location:"region between Lys-550 and Val-560"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1473..1481] Deletion))
      (PP-LOC (IN:[1482..1484] at)
        (NP
          (NP
             (NN:[1485..1490] codon) (CD:[1491..1494] 579)
            (PRN (-LRB-:[1495..1496] -LRB-)
              (NP (NN:[1496..1499] Asp))
              (-RRB-:[1499..1500] -RRB-)))
          (PP-LOC (IN:[1501..1503] in)
            (NP
              (NP (DT:[1504..1507] the) (NN:[1509..1522] juxtamembrane)
                  (NN:[1523..1529] domain))
              (PP (IN:[1530..1532] of)
                (NP (DT:[1533..1536] the) (NN:[1537..1542] c-kit)
                    (NN:[1543..1547] gene))))))))
    (VP (VBZ:[1548..1550] is)
      (NP-PRD
        (NP (DT:[1551..1552] a) (JJ:[1553..1558] novel)
          (NML
            (NML (NN:[1559..1563] gain))
            (HYPH:[1563..1564] -)
            (PP (IN:[1564..1566] of) (HYPH:[1566..1567] -)
              (NP (NN:[1567..1575] function))))
          (NN:[1576..1584] mutation))
        (ADJP
          (ADJP (JJ:[1586..1591] other))
          (PP (IN:[1592..1596] than)
            (NP
              (NP (DT:[1597..1600] the) (NN:[1601..1607] region))
              (PP-LOC (IN:[1608..1615] between)
                (NP (NN:[1616..1623] Lys-550) (CC:[1624..1627] and)
                    (NN:[1628..1635] Val-560))))))))
    (.:[1635..1636] .)))

;section 18 Span:1640..1684
;PMID: 9797363 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1640..1644] PMID) (::[1644..1645] :) (CD:[1646..1653] 9797363)
        (IN:[1654..1655] -LSB-) (NNP:[1655..1661] PubMed) (HYPH:[1662..1663] -)
        (JJ:[1664..1671] indexed) (IN:[1672..1675] for)
        (NNP:[1676..1684] MEDLINE-RSB-)))
